PB-1902 is under clinical development by PegBio and currently in Phase I for Opioid-Induced Constipation (OIC). According to GlobalData, Phase I drugs for Opioid-Induced Constipation (OIC) have an 80% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how PB-1902’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
PB-1902 overview
PB-1902 is under development for the treatment of opioid-induced constipation. It is administered through oral route. The drug candidate acts by targeting mu-opioid receptor.
PegBio overview
PegBio is a biopharmaceutical company, engages in manufacturing polyethylene glycol (PEG) and developing PEGylation technology, and develops PEG synthesis technology and solutions. PegBio is headquartered in Suzhou, Jiangsu, China.
For a complete picture of PB-1902’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
